English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduLearn how scientists at St. Jude are leading research to improve CAR T-cell therapy for osteosarcoma by enhancing chemokine homing.
Tag: CAR T-cell
New tech addresses manufacturing bottlenecks in a lifesaving blood cancer treatment
Relapsed B-cell ALL is the leading cause of cancer-related deaths in children and young adults. UniSA research has shown the potential of new microfluidic technology, to improve the CAR T-cell manufacturing process by efficiently removing contaminating cancerous cells and other large white blood cells – potentially leading to greater access and lower costs of treatment.
Launch of a pioneering translational research programme in Europe
– The TRIP initiative establishes three new joint laboratories that bring together fundamental biomedical research and clinical research with the aim of accelerating the delivery of results to patients.
– TRIP will focus on emerging fields such as immuno-oncology, inflammation, and cellular senescence.
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
Findings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.
New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
Chula Makes Progress in “CAR T-Cell Therapy” Innovation: New Hope for Thai Lymphoma Cancer Patients
Chulalongkorn University, Thailand, and Nagoya University, Japan, in their collaboration to develop an immunotherapy method for curing cancer, reported on the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients, which can increase survival rates and reduce cancer recurrence.
NCCN Annual Congress on Hematologic Malignancies™ Returns to In-Person October 14–15, 2022 in New York City
The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.